nach oben

CardioVascular and Interventional Radiology

Erschienen in:

01.02.2013 | Clinical Investigation

Radioembolization as Locoregional Therapy of Hepatic Metastases in Uveal Melanoma Patients

verfasst von: A. Klingenstein, A. R. Haug, C. J. Zech, U. C. Schaller

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To retrospectively evaluate the overall survival, safety, and efficacy of metastatic uveal melanoma patients after radioembolization as salvage therapy.

Materials and Methods

Thirteen patients were treated with radioembolization of branches of the hepatic artery with resin-based yttrium-90 (⁹⁰Y)-labelled microspheres. Twelve patients underwent a single application, and 1 patient underwent 4 interventions. Dosages from 644 to 2,450 MBq (mean activity 1,780) were applied. Treatment response was evaluated by way of liver magnetic resonance imaging and computed tomography (CT) as well as whole-body fluorodeoxyglucose positron emission tomography (PET)/CT with evaluation of percentage changes in SUV_max before and at 2–3 months after therapy. Kaplan–Meier analysis was calculated to determine overall survival.

Results

Partial remission (PR) was observed in 8 (62 %), stable disease (SD) in 2 (15 %), and progressive disease (PD) in 3 (23 %) patients under terms of standard criteria and PR in 3 (23 %), SD in 3 (23 %), and PD in 7 (54 %) patients according to PET criteria. Neither RECIST nor PET criteria showed a significant difference in predicting overall survival (P = 0.12 and 0.11, respectively). Median survival time after radioembolization was 7 months. No acute toxicity with in-hospital morbidity was observed. One patient developed hepatomegaly, and 1 patient developed gastric ulceration. Throughout follow-up, progression of extrahepatic metastases was observed.

Conclusion

Radioembolization may be a promising therapy in uveal melanoma patients with predominant hepatic metastases. At first follow-up, we observed PR or SD in 77 % patients under terms of standard criteria with an acceptable toxicity profile.

Damato B (2004) Developments in the management of uveal melanoma. Clin Exp Ophthalmol 32(6):639–667CrossRef

Peters S, Voelter V, Zografos L et al (2006) Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17:578–583PubMedCrossRef

Haritoglou I, Wolf A, Maier T et al (2009) Osteopontin and “melanoma inhibitory activity”: comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 223(4):239–243PubMedCrossRef

Schuster R, Lindner M, Wacker F et al (2010) Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 20(3):191–196PubMed

Kivelä T, Eskelin S, Kujala E (2006) Metastatic uveal melanoma. Int Ophthalmol Clin 46:133–149PubMedCrossRef

Schmittel A, Scheulen ME, Bechrakis NE et al (2005) Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 15:205–207PubMedCrossRef

Stubbs RS, O’Brien I, Correia MM (2006) Selective internal radiation therapy with ⁹⁰Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76:696–703PubMedCrossRef

Pöpperl G, Helmberger T, Münzing W et al (2005) Selective internal radiation therapy with SIR-Spheres^® in patients with nonresectable liver tumors. Cancer Biother Radiopharm 20(2):200–208PubMedCrossRef

Jakobs TF, Hoffmann RT, Tatsch K et al (2008) Therapieresponse von Lebertumoren nach selektiver interner Radiotherapie. Radiologe 48:839–849PubMedCrossRef

10.

Kucuk ON, Soydal C, Laci S et al (2011) Selective intraarterial radionuclide therapy with yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. World J Surg Oncol 9:86PubMedCrossRef

11.

Ho S, Lau WY, Leung TW et al (1997) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24:293–298PubMed

12.

Gray B, van Hazel G, Buck M et al (2000) Treatment of colorectal liver metastases with SIR-spheres plus chemotherapy. GI Cancer 3:249–257

13.

Stubbs RS, Cannan RJ, Mitchell AW (2001) Selective internal radiation therapy with ⁹⁰yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 5:294–302PubMedCrossRef

14.

Lewandowski RJ, Sato KT, Atassi B et al (2007) Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Interv Radiol 30(4):571–592CrossRef

15.

Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251–1278PubMedCrossRef

16.

Salem R, Lewandowski RJ, Gates VL et al (2011) Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 22(3):265–278PubMedCrossRef

17.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRef

18.

Haug AR, Heinemann V, Bruns CJ et al (2001) ¹⁸F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with ⁹⁰Y microspheres. Eur J Nucl Med Mol Imaging 28:1037–1045

19.

Barak V, Frenkel S, Kalickman I et al (2007) Serum markers to detect metastatic uveal melanoma. Anticancer Res 27:1897–1900PubMed

20.

Vente MA, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere SIRT for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19(4):951–959PubMedCrossRef

21.

Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103(3):324–331PubMedCrossRef

22.

Kennedy A, Nutting C, Jakobs T et al (2009) A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Investig 27:682–690CrossRef

23.

Farrag A, Ceulemans G, Voordeckers M et al (2010) Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 31:495–501PubMed

24.

Higashi T, Hatano E, Ikai I et al (2010) FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 37:468–482PubMedCrossRef

25.

Bienert M, McCook B, Carr BI et al (2005) 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 32(7):778–787PubMedCrossRef

26.

Szyszko T, Al-Nahhas A, Tait P et al (2007) Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun 28(1):21–24PubMedCrossRef

27.

Jiao LR, Szyszko T, Al-Nahhas A et al (2007) Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol 33:597–602PubMedCrossRef

28.

Haug AR, Schmidt GP, Klingenstein A et al (2007) F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 31(4):629–634PubMedCrossRef

29.

Klingenstein A, Haug AR, Nentwich MM et al (2010) Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma. Melanoma Res 20(6):511–516PubMedCrossRef

30.

Miller FH, Keppke AL, Reddy D et al (2007) Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. Am J Roentgenol 188(3):776–783CrossRef

31.

Wong CY, Qing F, Savin M et al (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 SIRT as evaluated by 18F fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16(8):1101–1106PubMedCrossRef

32.

Wang SC, Bester L, Burnes JP et al (2010) Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 54(3):178–187PubMedCrossRef

33.

Jakobs TF, Saleem S, Atassi B et al (2008) Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with ⁹⁰yttrium microspheres. Dig Dis Sci 53:2556–2563PubMedCrossRef

34.

Paprottka PM, Schmidt GP, Trumm CG et al (2011) Changes in normal liver and spleen volume after radioembolization with ⁹⁰Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance. Cardiovasc Interv Radiol 34:964–972CrossRef

35.

Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88(2):78PubMedCrossRef

Titel: Radioembolization as Locoregional Therapy of Hepatic Metastases in Uveal Melanoma Patients
verfasst von: A. Klingenstein
A. R. Haug
C. J. Zech
U. C. Schaller
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 1/2013
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-012-0373-5

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Radioembolization as Locoregional Therapy of Hepatic Metastases in Uveal Melanoma Patients

Abstract

Purpose

Materials and Methods

Results

Conclusion

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Radiologie

Springer Medizin

Abstract

Purpose

Materials and Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Preoperative Direct Puncture Embolization of Advanced Juvenile Nasopharyngeal Angiofibroma in Combination with Transarterial Embolization: An Analysis of 22 Consecutive Patients

Embolization of Incompetent Pelvic Veins for the Treatment of Recurrent Varicose Veins in Lower Limbs and Pelvic Congestion Syndrome

Evaluation of the Anti-migration Effect of Barbed Prostatic Stents: In Vitro Study in Urethra-mimicking Bovine Pericardium Phantoms

Alternative Techniques for Treatment of Complex Below-the Knee Arterial Occlusions in Diabetic Patients With Critical Limb Ischemia

Percutaneous Retrograde Recanalization of the Celiac Artery by Way of the Superior Mesenteric Artery for Chronic Mesenteric Ischemia

MINI PCNL in a Pediatric Population

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Radiologie